Goldman Sachs Starts TCR2 Therapeutics (TCRR) at Neutral
Tweet
Share
E-mailGet Alerts TCRR Hot Sheet
Price: $2.91 --0%
Rating Summary:
7 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 21 | New: 52
Rating Summary:
7 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 21 | New: 52
Trade Now!
Join SI Premium – FREE
Goldman Sachs analyst Madhu Kumar initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Neutral rating and a price target of $5.00.
For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.
Shares of TCR2 Therapeutics closed at $3.76 yesterday.
You May Also Be Interested In
- UPDATE: Northland Capital Markets Starts Cepton Inc. (CPTN) at Outperform
- Wedbush Assumes Uber Inc. (UBER) at Outperform
- Berenberg Starts Just Eat Takeaway.com NV (TKWY:NA) (GRUB) at Sell
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
